Showing 611-620 of 1100 results for "".
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet.
- When Lightning Strikes: A Case Study of Staphylococcal Scalded Skin Syndrome in a 55-year-old Manhttps://practicaldermatology.com/news/when-lightning-strikes-a-case-study-of-staphylococcal-scalded-skin-syndrome-in-a-55-year-old-man/2462042/Five months after being struck by lightning, a 55-year-old male presented with a 2-day history of an erythematous rash. The patient noted his skin had been excessively dry since the lightning strike, and he recently added a new essential oil to his bath. His medical history includes liver failure
- Measuring ctDNA May Lead to Alternative Treatment Options and Better Outcomes in Advanced Melanomahttps://practicaldermatology.com/news/measuring-ctdna-may-lead-to-alternative-treatment-options-and-better-outcomes-in-advanced-melanoma/2462040/Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study found that measuring ctDNA in the blood of patients with BRAF wild-type (BRAF WT) s
- Crown Therapeutics Rolls Out PanOxyl Clarifying Exfoliant, PanOxyl Adapalene 0.1% Gelhttps://practicaldermatology.com/news/crown-therapeutics-rolls-out-panoxyl-clarifying-exfoliant-panoxyl-adapalene-01-gel/2462039/Crown Therapeutics is launching two new PanOxyl products: PanOxyl Clarifying Exfoliant with 2% Salicylic Acid and PanOxyl Adapalene 0.1% Gel. PanOxyl Clarifying Exfoliant features a pH-balanced, alcohol-free formula that can be used daily without any harsh
- Can Phages Help Treat AD?https://practicaldermatology.com/news/can-phages-help-treat-adp/2462033/Bacteriophages or bacteria eaters may be a new therapy option for people with atopic dermatitis (AD), according to a study in Science Advances. A MedUni Vienna team has investigated t
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base
- Cetaphil Takes on Aging Skin with New Skincare Linehttps://practicaldermatology.com/news/cetaphil-takes-on-aging-skin-with-new-skincare-line/2461995/Galderma is rolling out Cetaphil Healthy Renew, its first-ever healthy aging skincare line. "Aging skin is a particular point of frustration for my sensitive skin patients due to increased risks of irritation and an already compromised skin barrier,” says Cetaphil partn